11.08.2015 07:00:00 CET
Helsinki, 11 August 2015 at 8:00 am
Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, announces that the United States Patent and Trademark Office ("USPTO") has now granted a key patent covering its method and system for displaying the electric field generated on the brain by transcranial magnetic stimulation (TMS).
Nexstim's Navigated Brain Stimulation (NBS) is the world's most advanced navigated TMS system and the only one able to model the electric field in the brain. E-field based navigation enables enhanced accuracy, repeatability and dose control, to transform TMS as a clinical tool for personalised therapy.
This approval is in addition to our patents granted in China and Japan.
TMS uses an induction coil in which a time-varying magnetic field is generated to induce an electric E-field within the brain. The neurons at the locations of the brain exposed to a strong enough E-field will become activated, or stimulated. In NBS, the E-field induced in the brain by a TMS induction coil device is shown as an overlay on a graphical display of an anatomical representation of the subject's brain. By viewing the display, a user can visualise the E-field and, therefore, interactively position the TMS coil device, in real time, in relation to the brain to stimulate a target site.
Janne Huhtala, Chief Executive of Nexstim, commented: "Nexstim's technology is leading the way in brain stimulation and this approval adds further global validation of our unique E-field navigation. Whilst already used in in our NBS system for pre-surgical mapping, this further strengthens our position as we near the first interim analysis in Q3 this year from our Phase III study in stroke therapy in the US."
Janne Huhtala, CEO
For further information please visit www.nexstim.com or contact:
Nexstim +358 (0)40 8615046
Janne Huhtala, Chief Executive Officer email@example.com
UB Capital Oy (Certified Adviser) +358 (0)9 2538 0225
Walter Ahlström / Tom Olsio
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan firstname.lastname@example.org
About Nexstim Plc
Nexstim, formed in 2000 and based in Finland, is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBT®). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBT® and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com.
Key Technology Patent Granted for US